Expert perspectives on cholangiocarcinoma (CCA)

I see CCA today (2022)

World CCA Day (12 February 2022), organised by the Global CCA Alliance, is an international effort to raise awareness of CCA. The purpose of Rare Disease Day (28 February 2022) is to raise awareness and generate change for the 300 million people worldwide living with a rare disease.¹ To support these initiatives, we asked a patient with CCA and a multidisciplinary panel of CCA experts to express how they #SeeCCA today.

Reference: 1. Nguengang Wakap S, et al. Eur J Hum Genet. 2020;28:165–73.

Helen Morement

CEO and Founder of AMMF - The Cholangiocarcinoma Charity, London, UK

Phil Preston

Patient,
UK

Dr Angela Lamarca

Fundación Jiménez Díaz University Hospital, Spain

Dr Joachim Mertens

University Hospital Zürich,
Zürich, Switzerland

Professor Juan Valle

University of Manchester & The Christie, Manchester, UK

Professor Thomas Gruenberger

HPB Center, Clinic Favoriten, Health Network Vienna,
Vienna, Austria

Professor Bruno Sangro

Clinica Universidad de Navarra, Pamplona, Spain

Dr Teresa Macarulla

Vall d’Hebron University Hospital,
Barcelona, Spain

Dr Ana Vivancos

Vall d’Hebron Institute of Oncology,
Barcelona, Spain

Glenda O’Connor

Lead Dietician,
The Princess Grace Hospital,
London, UK

CCA: under the spotlight (2021)

This online webinar took place on 26 February 2021 and was hosted by our esteemed faculty who critically discussed the complexity of diagnosing CCA and the clinical and genetic heterogeneity associated with the disease

Dr Teresa Macarulla

Vall d’Hebron University Hospital,
Barcelona, Spain

Dr Joachim Mertens

University Hospital Zürich,
Zürich, Switzerland

Dr Angela Lamarca

Fundación Jiménez Díaz University Hospital, Spain

Dr Coralie Sayag

Former Medical Director Solid Tumours,
Region Europe, Incyte Biosciences International Sàrl (01 May 2020 – 31 May 2022)

Company/Organisation	Relationship(s)
Albireo Pharma, AstraZeneca, Boehringer Ingelheim, Boston Scientific, Eisai, GenFit, Nutricia Ipsen, QED, Roche, Servier and TransThera Biosciences	Receipt of honoraria or consultation fees
AAA, AstraZeneca, Eisai, Incyte, Ipsen, Merck, Pfizer, QED, Roche and Servier	Participation in company-sponsored speaker bureau
AAA, Bayer, Delcath, Ipsen, Mylan, Novartis, Pfizer and Sirtex	Travel, education funding
Ipsen and Roche	Research funding

Company/Organisation	Relationship(s)
Imaging Equipment Ltd, Ipsen, Novartis, NuCana	Speakers bureau
Celgene, NuCana	Travel grant
Agios, AstraZeneca, Debiopharm, Delcath Systems, GenoScience Pharma, Imaging Equipment Ltd, Incyte, Ipsen, Keocyt, Merck, Mundipharma EDO, Novartis, NuCana, PCI Biotech, Pieris Pharmaceuticals, Pfizer, QED, Servier, Wren Laboratories	Grant support

Company/Organisation	Relationship(s)
Adaptimmune, AstraZeneca, Bayer, Bristol Myers Squibb, Boston Scientific, Eisai, Exelixis, Ipsen, Lilly, Merck, Novartis, Roche, Sirtex Medical, Terumo	Consulting, advisory role or honoraria
Bristol Myers Squibb, Sirtex Medical	Grants

Company/Organisation	Relationship(s)
Albireo Pharma, AstraZeneca, Boehringer Ingelheim, Boston Scientific, Eisai, GenFit, Nutricia Ipsen, QED, Roche, Servier and TransThera Biosciences	Receipt of honoraria or consultation fees
AAA, AstraZeneca, Eisai, Incyte, Ipsen, Merck, Pfizer, QED, Roche and Servier	Participation in company-sponsored speaker bureau
AAA, Bayer, Delcath, Ipsen, Mylan, Novartis, Pfizer and Sirtex	Travel, education funding
Ipsen and Roche	Research funding

Expert perspectives on cholangiocarcinoma (CCA)

I see CCA today (2022)

CCA: under the spotlight (2021)

All videos in this category

I see CCA today (2022)

CCA: under the spotlight (2021)

Enhance your CCA knowledge with Incyteful